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Edited by Ivan SadowskiAbstract By bioluminescence imaging and hydrodynamic gene
transfer technology, the activities of hepatitis B virus (HBV) pro-
moters and the eﬀects of HBV enhancers on these promoters in
mice under true physiological conditions have been assessed. Our
studies reveal that either of the two HBV enhancers can stimu-
late HBV major promoter activity in hepa 1–6 cells (in vitro)
and in mouse liver (in vivo), and the enhancer eﬀects on the three
promoters (S1, S2 and X promoter) are markedly greater in vivo
than in vitro. The two HBV enhancers have no cooperative ac-
tion on HBV promoters in vitro or in vivo.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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imaging1. Introduction
Hepatitis B virus (HBV) is a human hepadnavirus that is
known to cause persistent infection and chronic hepatitis, cir-
rhosis and hepatocellular carcinoma (HCC). The HBV genome
is a circular, partially double-stranded DNA molecule contain-
ing four, partly overlapping, open reading frames (ORFs) [1].
Transcription is initiated by four promoters: S1 promoter, S2
promoter (also named preS promoter and S promoter), the
core promoter and X promoter. The core promoter plays a
central role in HBV replication and morphogenesis, directing
the transcription of 3.5 kb mRNA. S1 and S2 promoter respec-
tively direct the transcription of the 2.4 kb large surface pro-
tein (LHBsAg) mRNA and a group of 2.1 kb mRNAs with
heterogeneous 5 0ends by using diﬀerent transcription start
sites, and X promoter directs the synthesis of X mRNA. The
activities of these four promoters are regulated by two enhan-
cer elements: enhancer I (En I) and enhancer II (En II) [2–5].
Enhancer I spans a sequence of about 160 bp which is adjacent
to the X promoter and has the classical ability to up-regulateAbbreviations: HBV, hepatitis B virus; HCC, hepatocellular carci-
noma; ORFs, open reading frames; LHBsAg, large surface protein; En
I, enhancer I; En II, enhancer II; CMV, cytomegalovirus; BCP, basal
core promoter.
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II is 148 bp in length, and is located immediately upstream of
the basal core promoter (BCP) on the HBV genome and is part
of the core promoter. Both enhancers are liver-speciﬁc and en-
hance the activity of the four HBV promoters [6–9].
The activities of the individual (HBV) promoters and the ef-
fects of the HBV enhancer on these promoters in several hu-
man cell types have been compared by measuring the activity
and RNA levels of the linked reporter gene (including chlor-
amphenicol acetyltransferase and luciferase) [4,6–8]. Although
these in vitro systems are available and easy to perform, they
suﬀer from the common problem that many tissue speciﬁc
transcription factors are lost when cells are kept in an artiﬁcial
environment for an extended period of time. Now we have
constructed transient mouse model by hydrodynamic gene
transfer to examine the activity of promoters and the eﬀect
of the HBV enhancers on the activity of the promoters in
whole animals under true physiological conditions by the IVIS
camera, which provides quantitative bioluminescence imaging
of live mice [10–12].2. Materials and methods
2.1. Plasmid construction
All four HBV promoter sequences and two enhancer sequences were
selected based on previously published gene sequence and synthesized
by PCR using HBV DNA (ayw serotype, accession no. AY661792) as
the template. The core promoter (1591–1822) was PCR ampliﬁed with
primers 5 0-CGAGCTCCAAGGTCTTACATAAG-30/5 0-CCAAG
CTTTGGAGGCTTGAAC AGT-3 0; the S1 promoter (2219–2780)
with primers 5 0-CGAGCTCTGTCTCACTTTTGGAAG-30/5 0-
CCAAGCTTTTATATAATATACCCGCC-3 0; the S2 promoter
(2809–3152) with primers: 5 0-CGAGCTCTTTGTGGGTCACCATA-
3 0/5 0-CCAAGCTTCCTGACTGGCG ATTGGT-3 0; the X promoter
(1235–1374) with primers 5 0-CGAGCTCTGCGTGGAACC TTTTC-
3 0/5 0-CCAAGC TTGGAAACGATGTATATT-3 0; the En I (1070–
1234) with primers 5 0-GGGTACCGTATTCAA TCTAAGCA-3 0/5 0-
CGAGCTCTGCGCTGATGGC CCATGA-3 0; the En II (1627–
1774) with primers 5 0-GGGGTACCCCCACCAAATATTGCC-30/5 0-
CGAGCTCTAGTACAAAGACCTT T-3 0 and 5 0-CGGGATCCCC-
CACCAA ATATTGCC-3 0/5 0-GCGTCGACTAGTACAAAGACCT
TT-3 0; the cytomegalovirus (CMV) Enhancer/Promote with primers
5 0-GGGTACCTCAATATTGGCCATTA-3 0/5 0-CAAGCTTGATC
TGACGGTTCACT-3 0. All ampliﬁed promoter sequences were cloned
into pGL3-basic vector (Promega, Madison, WI) by ligating the puri-
ﬁed PCR fragments and linearized pGL3-basic vector after digestion.
Each insertion in the plasmid construct was conﬁrmed by restriction
enzyme digestion and sequence analysis. Plasmids were transformed
into Escherichia coli (strain DH-5a) and puriﬁed by the Qiagen-plas-
mid puriﬁcation kits (Hilden, Germany).blished by Elsevier B.V. All rights reserved.
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Hepa 1–6 cells from mouse hepatocellular carcinomas were
purchased from ATCC (Manassas, VA) and cultured in DMEM
(Gibco, Carlsbad, CA) supplemented with 10% FBS (HyClone, South
Logan, UT); and were kept in a 5% CO2 incubator at 37 C. The
transfection experiments were conducted by using Lipofectamine 2000
(Invitrogen, Carlsbad, CA), following the manufacturers instructions.
In brief, 1 lg of a plasmid DNAmixture was used for each transfection
reaction for one well of a twenty-four-well plate, containing 4.0 · 105
Hepa 1–6 cells.
2.3. Mice
Balb/c mice (male, 18–20 g) were maintained at the animal facility of
Academy of MilitaryMedical Sciences in a speciﬁc pathogen-free unit,
under a 12 h light/dark cycle, and were provided with food and water.
2.4. Hydrodynamic tail-vein injections
Balb/c mice were rapidly injected via the tail vein with 1.6 ml saline
containing 20 lg of plasmid DNA. The total volume was injected rap-
idly, over 5–8 s, into the tail-vein of a mouse.
2.5. In vivo and in vitro luciferase activity monitoring by the IVIS camera
For in vitro bioluminescence imaging, the cells were harvested and
resuspended in 100 ll PBS, 8 min before monitoring light emission,
100 ll (1 mg/ml in PBS) of D-luciferin was added to the cell suspension.
Cells were then scanned for 30 s using the Xenogen IVIS-50 optical
imaging system (Xenogen Corporation, Alameda, CA). For in vivo
bioluminescence imaging, mice which were transfected with ﬂy lucifer-
ase reporter gene were anesthetized, and 8 min before monitoring light
emission, the animals were injected with 100 ll (15 mg/ml in PBS) of
D-luciferin i.p. Mice were then scanned for 1 min using the Xenogen
IVIS-50 optical imaging system. Regions of interest (ROI) were drawn
by the instrument automatically, resulting that 90% of the biolumines-
cence signal is contained inside ROI. The quantiﬁcation is reported as
the maximum photon ﬂux within ROI. The bioluminescence signal is
represented as photons/s/cm2/sr.
2.6. Immunohistochemistry
Mice were killed at 24 h after the hydrodynamic injection. Liver tis-
sues were ﬁxed in 10% formaldehyde, embedded with paraﬃn and cut
into 4 lm thick sections. For luciferase detection, the sections were
incubated with goat anti-luciferase antibody (Rockland Immunochem-
icals Inc.), and were detected by DAB staining. The liver sections were
also stained with hematoxylin.
2.7. Statistics
Statistical analysis was performed with Students t-test for quantita-
tive variables. Quantitative data are expressed as the means ± S.D.
P < 0.05 was considered to be statistically signiﬁcant.3. Results
3.1. Comparison of HBV promoters activity in vitro and in vivo
To determine the relative strengths of the four HBV promot-
ers, we constructed plasmids containing the ﬂy luciferase gene
linked to the four HBV promoters respectively, pS1-Luc, pS2-
Luc, pC-Luc, and pX-Luc. These plasmids were transfected
into the liver cell line Hepa 1–6 and mouse liver. The relative
transcriptional activities of the four HBV promoters in vivo
and in vitro were screened by the IVIS camera and compared
(Fig. 1A and B). Immunohistochemical staining was per-
formed to examine luciferase expression in the liver. As illus-
trated in Fig. 1C, in the animals injected with pCMV-Luc,
the liver cells were stained positive by anti-luciferase antibody.
Fig. 1D shows in vitro, that among the ﬁve plasmids evaluated,
the CMV promoter provides the highest luciferase gene expres-
sion, and the S1, S2 promoter exhibit the lowest level activity,
approximately two orders of magnitude lower than that ofCMV. The promoter strength for core promoter (including en-
hancer II) and X promoter is one order of magnitude lower
than that of CMV. The overall order of activity based on
the luciferase activity is as follows: CMV > C, X > S1, S2. In
vivo, the CMV promoter provides the highest luciferase
expression also, and the S1, X promoter exhibit the lowest level
of luciferase activity, approximately three orders of magnitude
lower than that of CMV. The S2 promoter exhibits lower
activities, approximately two orders of magnitude lower than
that of CMV. The promoter strength for core promoter
(including enhancer II) is at the same order of magnitude of
CMV. The overall order of activity based on the luciferase
activity is as follows: CMV > C > S2 > S1, X.3.2. Enhancer regulation of HBV S1 and S2 promoter activities
in vitro and in vivo
To determine how the two enhancers aﬀect HBV S1 pro-
moter activity and whether the two enhancers interact cooper-
atively to modulate HBV gene expression, we have constructed
plasmids containing the ﬂy luciferase gene linked to the HBV
S1 promoters with one or two HBV enhancers respectively.
We transfected these plasmids into the mouse liver and cell line
Hepa 1–6, respectively, and luciferase activity was determined
by the IVIS camera and normalized to that of pS1-Luc with no
enhancer (Fig. 2). In Hepa 1–6 cells, En I in pEIS1-Luc stim-
ulates luciferase expression 3-fold, whereas pEIIS1-Luc gen-
erates levels of luciferase activity similar to that of pS1-Luc.
pES1-Luc which has two enhancers fails to produce higher lev-
els of luciferase activity than pEIS1-Luc, suggesting that En II
has no activity and En I alone stimulates the promoter activity
in Hepa 1–6 cells. In vivo, S1 promoter activity is stimulated
>60-fold by En I, and it is stimulated 34-fold by En II. Lucif-
erase activity produced by pES1-Luc with both enhancers is
comparable to that of pEIS1-Luc, suggesting that En II is dis-
pensable for S1 promoter activity in mouse liver. As shown in
Fig. 2, the stimulatory eﬀect of En I on S1 promoter is stronger
than that of En II in vitro and in vivo.
Similar plasmids using the S2 promoter instead of the S1
promoter to regulate luciferase gene expression were con-
structed, and the results of transfection with these plasmids
are shown in Fig. 3. In Hepa 1–6 cells, S2 promoter activity
is stimulated 6-fold by En I (pEIS2-Luc), 2-fold by En II
(pEIIS2-Luc) and 5-fold by two enhancers (pES2-Luc), sug-
gesting that luciferase expression from S2 promoter is solely
depend on En I, just like the S1 promoter. In mouse liver,
S2 promoter activity is stimulated 17-fold by En I and 14-fold
by En II. pES2-Luc which have two enhancers generates levels
of luciferase activity similar to that of pEIIS2-Luc, suggesting
that both En I and En II are important to stimulates transcrip-
tional activity of S2 promoter in vivo. As shown in Fig. 3, the
stimulatory eﬀect of En I on S2 promoter is stronger than that
of En II in vitro, but is similar to En II in vivo.3.3. Enhancer regulation of HBV X promoter activities in vitro
and in vivo
Similar plasmids using the X promoter instead of the S1 pro-
moter to regulate luciferase gene expression were constructed,
and the results of transfection with these plasmids are shown
in Fig. 4. X promoter activity is stimulated to the maximum
level by En I alone, suggesting that En I is indispensable
for X promoter activity. In mouse liver, X promoter activity
Fig. 1. (A, B) Bioluminescence imaging luciferase expression in mice and in cell line Hepa 1–6: they were transfected with ﬁve plasmids pCMV-
Luc(1), pS1-Luc(2), pS2-Luc(3), pC-Luc(4) and pX-Luc(5). (C) Immunohistochemical analysis of luciferase expression in liver tissues of mice.
Animals were hydrodynamically transfected with pCMV-Luc or pGL3-basic plasmid, and the expression of luciferase in liver was detected by
immunohistochemical staining at 24 h after the hydrodynamic injection. Magniﬁcation 100·. (D) Evaluation of promoters for driving luciferase
expression in vivo and in vitro. Luciferase activity was analyzed 24 h after transfection. Values represent means ± S.D. (n = 3). #P < 0.05 compared
with pCMV-Luc group; *P < 0.05 compared with pS1-Luc group; **P < 0.05 compared with pS2-Luc group; ***P < 0.05 compared with pC-Luc
group.
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Luc with two enhancers generates levels of luciferase activity
similar to that of pEIIX-Luc. Diﬀerent from that in Hepa 1–6
cells, either En I or En II is able to stimulate X promoter activity
to the high level in vivo. As shown in Fig. 4, the stimulatory ef-
fect of En I onX promoter is stronger than that of En II in Hepa
1–6 cells, but is similar to En II in vivo, just like S2 promoter.
3.4. Enhancer regulation of HBV core promoter activities
in vitro and in vivo
Because En II is part of the core promoter, we cannot sepa-
rate En II from the core promoter, the plasmids with En II andwith two enhancers were constructed, and the results of trans-
fection with these two plasmids are shown in Fig. 5.
The luciferase activity of pEC-Luc with both enhancers is
approximately 6-fold higher than the activity of pEIIC-Luc
with En II alone, suggesting that the activity of En I is impor-
tant for regulating core gene expression in this cell line. In vivo,
the luciferase activity of pEC-Luc with both enhancers is sim-
ilar to that of pEIIC-Luc with En II alone, indicating that En I
is dispensable for core promoter activity in mouse liver. Be-
cause we have not yet been able to separate En II activity from
the core promoter activity, assessment of the eﬀect of En I
alone on core promoter activity is not possible.
Fig. 2. Activation of HBV S1 promoter activity by two HBV
enhancers in cell line Hepa 1–6 and in mouse liver. Luciferase activity
was analyzed 24 h after transfection. Luciferase activity of plasmid
pS1-Luc in vivo and in vitro was deﬁned as 1. Values represent
means ± S.D. (n = 3). *P < 0.05 compared with pS1-Luc group;
**P < 0.05 compared with pEIS1-Luc group; #P < 0.05 compared with
pES1-Luc group.
Fig. 3. Activation of HBV S2 promoter activity by two HBV
enhancers in cell line Hepa 1–6 and in mouse liver. Luciferase activity
was analyzed 24 h after transfection. Luciferase activity of plasmid
pS2-Luc in vivo and in vitro was deﬁned as 1.Values represent
means ± S.D. (n = 3). *P < 0.05 compared with pS2-Luc group;
**P < 0.05 compared with pEIS2-Luc group; #P < 0.05 compared with
pES2-Luc group.
Fig. 4. Activation of HBV X promoter activity by two HBV enhancers
in cell line Hepa 1–6 and in mouse liver. Luciferase activity was
analyzed 24 h after transfection. Luciferase activity of plasmid pX-Luc
in vivo and in vitro was deﬁned as 1.Values represent means ± S.D.
(n = 3). *P < 0.05 compared with pX-Luc group; **P < 0.05 compared
with pEIX-Luc group; #P < 0.05 compared with pEX-Luc group.
Fig. 5. Activation of HBV core promoter activity by two HBV
enhancers in cell line Hepa 1–6 and in mouse liver. Luciferase activity
was analyzed 24 h after transfection. Luciferase activity of plasmid pC-
Luc in vivo and in vitro was deﬁned as 1. Values represent
means ± S.D. (n = 3). *P < 0.05 compared with pEIIC-Luc group.
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in vivo and in vitro is summarized in Table 1.4. Discussion
Now we examine the activity of HBV four promoters in mice
and in Hepa 1–6 cells by bioluminescence imaging. The order
in Hepa 1–6 cells is C, X > S1, S2 which is consistent with the
previous observation in human cell lines such as HepG2, HeLa
and HS27 cells [7,8]. This order in vivo is C > S2 > S1, X, and
is diﬀerent from that in vitro. This suggests that the promoter
activity in whole animals under true physiological conditions is
diﬀerent from the activity in vitro.
HBV enhancer I has previously been shown to contain over-
lapping binding sites for multiple transcription factors includ-
ing HNF3, HNF4, C/EBP, AP-1, CREB, and ATF [13–15].
The ubiquitous distribution of some of these transcriptional
factors may account for this enhancer functions in many kinds
of cell lines such as human hepatoma cells (PLC/PRF/5,
Hep3B, HepG2,Huh7, and Huh6 cells) [3,7,16], non-liver cells
(HeLa, HS27 cells) [8]. In contrast, enhancer II activity is
strictly liver-speciﬁc, and its activity is highly variable in the
diﬀerent hepatoma lines used [5,17]. These may explain our re-
sults that either of the two HBV enhancers can stimulate S1, S2
and X promoter activity in Hepa 1–6 cells, but the stimulatory
eﬀect of En I is much stronger than that of En II. Although the
hepatitis B viral enhancer behaves as a classic cis activator in
the sense that it is active in both orientations, its activity is
strongly inﬂuenced by the nature of the cell in which it oper-
ates. In the Hepa 1–6 cells tested, the HBV enhancers modestly
stimulate three HBV promoters (S1, S2 and X promoter) activ-
ity (2–13-fold by En I and 2–7-fold by En II). In contrast, the
HBV enhancers stimulate the three promoters activity dramat-
ically (17–180-fold by En I and 14–140-fold by En II) in the
mouse liver. The stimulatory eﬀects of the two enhancers on
the three promoters are much stronger in vivo than that
in vitro. Our studies also show that in Hepa 1–6 cells, the stim-
ulatory eﬀect of En I on S1, S2 and X promoter is stronger
than that of En II, but in vivo, the eﬀect of En I on S2 and
X promoter is similar to that of En II.
Table 1
HBV enhancer activity on diﬀerent promoters in vitro and in vivo
Construction HBV enhancer activity, -fold induction
Without En With En I With En II With En I + II
In Hepa 1–6 cellsa
S1-Luc 1.0b 2.7 1.4 3.3
S2-Luc 1.3 7.3 3.0 5.9
C-Luc NAc NA 4.1 24
X-Luc 2.9 38 20 34
In mouse liverd
S1-Luc 1.0b 64 34 63
S2-Luc 4.1 68 59 57
C-Luc NA NA 150 240
X-Luc 1.2 221 170 171
aValues for the Hepa 1–6 cell line are normalized to luciferase activity of pS1-Luc with no enhancer in Hepa 1–6 cells.
bThe actual value represented by 1 in the mouse liver is 20 times greater than the values represented by 1 Hepa 1–6 cell line.
cNA £¨Construct was not available.
dValues for the mouse liver are normalized to luciferase activity of pS1-Luc with no enhancer in mouse liver.
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interact cooperatively to stimulate HBV S (S2) promoter activ-
ity in Huh7 and HepG2 cells and to stimulate HBV preS (S1)
promoter activity in Huh6 cells [7,8]. But in our test, the most
eﬃcient luciferase expression comes from pEIS1-Luc, pEIS2-
Luc and pEIX-Luc which have En I alone, indicating that
the two HBV enhancers cannot interact cooperatively to stim-
ulate HBV promoters activity in vivo and in vitro.
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